Jazz Pharmaceuticals JAZZ Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$368.44M+9.0% | -$404.8M-184% | $482.24M-13.9% | ||
| $40.34M-3.1% | $41.64M-0.2% | $41.72M+5.3% | $39.62M+11.6% | $35.5M+8.4% | ||
| $297.93M+2.3% | $291.13M+0.2% | $290.47M+10.8% | $262.1M+3.1% | $254.3M+2.5% | ||
| -$467.37M-5.0% | -$444.97M-15.9% | -$384.02M-117% | -$177.01M+4.7% | -$185.74M+10.8% | ||
| —— | —— | —— | —— | $0— | ||
| $178.78M+68.2% | $106.28M+163% | $40.47M+245% | $11.73M+122% | -$52.46M-339% | ||
| $135.96M+45.0% | $93.76M-16.6% | $112.43M+25.2% | $89.8M+31.5% | $68.3M+50.0% | ||
| —— | —— | —— | —— | —— | ||
| -$111.8M-245% | $77.1M-4.4% | $80.66M+1,393% | $5.4M— | —— | ||
| -$81.68M-181% | -$29.03M-230% | $22.25M-50.5% | $44.92M-3.4% | $46.48M-6.7% | ||
| $37.32M+33.2% | $28.02M+182% | -$34.3M-5.0% | -$32.67M+5.4% | -$34.53M+16.3% | ||
| —— | —— | -$8.06M+27.6% | -$11.14M-814% | $1.56M+108% | ||
| —— | —— | $37.17M+40.3% | $26.5M+260% | -$16.6M-12.6% | ||
| $672.51M+2.7% | $654.61M+1.7% | $643.77M+1.7% | $632.86M+1.1% | $625.98M-0.2% | ||
| $1.33B-1.6% | $1.36B-2.6% | $1.39B+5.8% | $1.32B-15.6% | $1.56B+11.6% | ||
| $64.55M+9.9% | $58.75M+6.2% | $55.31M+8.6% | $50.92M+13.0% | $45.07M+18.4% | ||
| $1.89B+3.3% | $1.83B+2.2% | $1.79B+39.8% | $1.28B-6.6% | $1.37B+5.0% | ||
| $1.57B+15.4% | $1.36B-7.5% | $1.47B+3.2% | $1.43B+37.7% | $1.04B+22.5% | ||
| —— | —— | —— | —— | $0— | ||
| $83.5M-23.0% | $108.5M+97.3% | $55M+120% | $25M0.0% | $25M— | ||
| -$1.22B+19.3% | -$1.51B-13.4% | -$1.33B— | —— | —— | ||
| $129.26M+19.8% | $107.86M+238% | $31.87M+2.3% | $31.16M-1.6% | $31.65M+53.3% | ||
| $111.62M+48.4% | $75.22M-2.6% | $77.23M+2.9% | $75.02M-0.8% | $75.66M+31.0% | ||
| -$213.82M+77.5% | -$948.82M— | —— | —— | —— | ||
| $4.46M-32.0% | $6.56M+54.9% | $4.23M-40.4% | $7.1M+312% | $1.72M+203% | ||
| —— | —— | —— | -$165.92M-140% | $418.48M-53.8% | ||
| —— | $248.55M-6.2% | $265.12M-5.9% | $281.69M-5.6% | $298.25M-5.3% | ||
| —— | $121.81M+1.4% | $120.08M+1.5% | $118.36M+1.5% | $116.63M+1.5% | ||
| $672.51M+2.7% | $654.61M+1.7% | $643.77M+1.7% | $632.86M+1.1% | $625.98M-0.2% | ||
| $40.34M-3.1% | $41.64M-0.2% | $41.72M+5.3% | $39.62M+11.6% | $35.5M+8.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $155.55M+5.1% | $147.95M+1.9% | $145.14M+3.8% | $139.82M+2.8% | $135.97M+0.7% | ||
| $20.14M-38.1% | $32.54M+7.4% | $30.31M-7.3% | $32.69M-1.2% | $33.09M+50.6% | ||
| —— | —— | -$8.06M+27.6% | -$11.14M-814% | $1.56M+108% | ||
| $28.01M+46.6% | $19.11M-28.9% | $26.89M+26.0% | $21.34M-16.8% | $25.66M-7.6% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $83.5M-23.0% | $108.5M+97.3% | $55M+120% | $25M0.0% | $25M— | ||
| —— | —— | —— | —— | —— | ||
| $1.57B+15.4% | $1.36B-7.5% | $1.47B+3.2% | $1.43B+37.7% | $1.04B+22.5% | ||
| —— | —— | —— | —— | $0— | ||
| $129.26M+19.8% | $107.86M+238% | $31.87M+2.3% | $31.16M-1.6% | $31.65M+53.3% | ||
| $31M-96.0% | $781M0.0% | $781M0.0% | $781M0.0% | $781.05M+2,420% | ||
| —— | $121.81M+1.4% | $120.08M+1.5% | $118.36M+1.5% | $116.63M+1.5% | ||
| $1.27B-2.1% | $1.3B-3.0% | $1.34B+5.7% | $1.27B-16.4% | $1.51B+11.5% | ||
| $1.27B-2.1% | $1.3B-3.0% | $1.34B+5.7% | $1.27B-16.4% | $1.51B+11.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Jazz Pharmaceuticals generate?
- Jazz Pharmaceuticals (JAZZ) generated $1.3B in operating cash flow over the trailing twelve months.
- What is Jazz Pharmaceuticals's free cash flow?
- After $64.6M of capital expenditures, Jazz Pharmaceuticals's free cash flow was $1.3B over the trailing twelve months, down 16.1% year over year.
- Where does Jazz Pharmaceuticals's cash flow data come from?
- Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
